KMT Hepatech, Inc. is a private company, which was founded in 2001 by Dr. Norman Kneteman, Dr. David Mercer and Dr. Lorne Tyrrell as a spin off company from the University of Alberta. The platform technology, the KMT MouseTM, is named after Drs. Kneteman, Mercer and Tyrrell.
Dr. Kneteman hypothesized that developing a method to support human liver cells in a mouse should allow support of Hepatitis C (HCV) infection, and yield a research model that would be invaluable to researchers. The attention was focused on immune deficient mice, as these mice could not reject the human liver cells when they are transplanted. A way to disadvantage a healthy mouse’s liver and enable the human liver cells to grow and replicate in the mouse model was found through the use of transgene that causes liver failure.
“Our Eureka moment was when Dr. Mercer got a call from the lab saying they had a positive test for Hep C, but that it must be a mistake, since the requisition said it was from a mouse. We knew then our research worked and we could grow human liver cells and infect these mice with Hep C,” says Dr. Kneteman.
The KMT MouseTM was widely used for drug discovery, development and pre-clinical studies. It provides an authentic viral infection model utilizing transplanted human liver cells infected with virus or parasite in a true in-vivo setting. Non-infected mice with humanized liver are utilized in safety/ toxicity and drug metabolism studies.
In 2017 KMT Hepatech became part of PhoenixBio group and will continue operations utilizing PXB-Mouse®
|KMT Hepatech owns international patent portfolio which covers the Alb/ uPA/SCID chimeric mouse model
is a cDNA-uPA/SCID chimeric mouse with more than 70% of liver replaced with human hepatocytes
The KMT MouseTM
was the trade name for proprietary KMT Hepatech, Inc. chimeric mouse with humanized liver (uPA+/+/SCID mice transplanted with human hepatocytes)
| Contact Us for more information